Panelists discusses how the "vicious vortex model" explains bronchiectasis pathophysiology, where airway dilatation leads to mucus stagnation, chronic infections, and neutrophilic inflammation, ...

Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms. Panelists discusses how the ...

Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...

This activity is provided by National Jewish Health. Bronchiectasis is a complex and increasingly prevalent condition often overlooked in clinical practice, with frequent overlap with other ...

Background and Objective: Bronchiectasis, which was previously regarded as a rare condition, has recently attracted increased attention with advancements in research and therapeutic strategies.

Bronchiectasis is a chronic respiratory disorder characterised by irreversible dilation of the bronchi, leading to impaired mucociliary clearance, recurrent infections and progressive respiratory ...

Most often secondary to childhood infection, bronchiectasis is irreversible. But there are steps you can take to improve your patients’ quality of life. Bronchiectasis, which is characterized by ...

The color of the phlegm from patients with the lung disease bronchiectasis can indicate the degree of inflammation in their lungs and predict their future outcomes, according to new research presented ...

FIRS organizations, including the American Thoracic Society, call for improving early detection of bronchiectasis. July 1, 2025 – According to the 2022 Global Impact of Respiratory Disease Report, the ...

— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed (INSM) to Host Investor ...

— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — BRIDGEWATER, N.J., Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated (INSM ...